l1-79
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2016 (NCT02947048)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Tyrosine 3-hydroxylaseINHIBITOR
TH inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- l1-79
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05067582 | Phase 2 | Nov 30, 2021 | Yamo Pharmaceuticals |
| NCT02947048 | Phase 2 | Oct 1, 2016 | Yamo Pharmaceuticals, Yamo Pharmaceuticals LLC |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Yamo Pharmaceuticals | For profit | 2 | 1 | 1 | 2016 |
| Yamo Pharmaceuticals LLC | Academic/Hospital | 1 | 1 | 1 | 2016 |
2 organizations
Page 1 / 1